Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs

Executive Summary

Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.

You may also be interested in...



The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.

Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.

The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.

Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.

Ilex Finds Comfortable Niche As Wall Street Attitude Towards CROs Sours

Ilex Oncology's combination of contract research and a proprietary pipeline is finding favor on Wall Street as the CRO industry overall weathers a slump.

Related Content

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel